Expression and purification of recombinant proteins
At Biomedal we propose a wide range of systems, strains and vectors. We have the most advanced technology to offer five expression systems with different performances and possibilities for post-translational modifications. We guarantee a prior technical evaluation of the project to ensure the client’s expectations.
In addition, if you do not know the most appropriate system for your case, we offer expression packages in multiple systems.
More than 10 years of experience in the production of recombinant proteins in E. coli from mg to grams, both in flasks and in large-scale fermetators. E. coli is the most widespread system in biotechnology for the expression of recombinant proteins. It offers a high success rate, high performance in various production conditions unlike other systems.
B. subtilis is commonly used for its properties to express proteins without endotoxins, and in some cases, it is an alternative to E. coli to increase the yield or purity of the product.
The proteins expressed in yeast are generally highly glycosylated. Our experience in the production of recombinant proteins in Pichia pastoris and Saccharomyces cerevisiae allows us to adapt to the needs and budget of the researcher. With our High Performance Screening Platform we evaluate several thousand conditions in a few weeks.
Insect cells are used to express recombinant proteins with complex post-translational modifications. Glycosylation is not the same as in mammalian cells, but sometimes enough to get functional proteins. This production process requires preparing the baculovirus, transfecting Sf9, Sf21 or Hi5 cells and performing 2 cycles of infection. This system is also known as BEVS, which stands for Baculovirus Expression Vector System.
Mammalian cells are used to make mammalian proteins that are most similar to nature.
Among the services included we find:
- Evaluation of the basic expression of recombinant proteins and antibodies
- High throughput screening of condition expression
- Humanization of antibodies
- Production in flasks and bioreactors up to 120L
- Production of bispecific antibodies
- Development of stable cell lines
- Optimization of the development process
- Master and working cell bank production
- Production of recombinant protein with stable isotopic labeling